Headlands Research, a clinical trial site network with locations across the U.S. and Canada, has made its first step into the ...

Following long-time chief José Almeida’s retirement earlier this year, Baxter announced it has officially named a new CEO. | ...

To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Chugai, a Japanese company majority owned by Roche, has identified Gero’s platform as complementary to its own capabilities.

In the July 2 release, 4DMT explained that the 25% layoffs are part of a move to “streamline operations to offset additional ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

University of Minnesota spinout Fasikl has obtained an FDA clearance for its artificial-intelligence-powered wearable for ...

Field Medical has generated another $35 million in venture capital funding for its cardiac pulsed field ablation system to support the launch of a pivotal trial. | The series B financing comes quickly ...

Catalio Capital Management has closed its fourth venture fund with more than $400 million that will be used in part to launch ...

AbbVie is on board with the idea. The Big Pharma will pay up to $2.1 billion in cash at closing to acquire Capstan. In return ...